1st Order Pharmaceuticals Inc: 1OP-2198

Discussion in 'Research News' started by Mic, Jan 25, 2017.

    1. DebInAustralia
      No Mood

      DebInAustralia Member Benefactor Advocate

      Geelong, Victoria
      Tinnitus Since:
      I skimmed through thread. Has the phase 3 trial begun?

      How long will this trial take?

      Has this drug been tested for tinnitus?

      Will this drug be available off label for tinnitus?
      • Good Question Good Question x 1
    2. Autumnly

      Autumnly Member Podcast Patron Benefactor Ambassador Hall of Fame Advocate

      Tinnitus Since:
      Cause of Tinnitus:
      • Phase III trial is supposed to start before the end of 2020
      • Kv7 potassium channel modulator, is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of epilepsy
      • currently in Phase 2b “X-TOLE”, topline data is anticipated in the first half of 2021
      • Novel, Next‐Generation KCNQ2 Modulator for the Treatment of Epilepsy
      • improved version of ezogabine; might help with tinnitus since some patients reported benefit from using ezogabine but "there is very limited clinical data and yet no evidence in humans for an effect of Kv7 channel modulation on tinnitus" source
      • Other potential indications for XEN1101 include tinnitus and ALS. source
      • ezogabine/retigabine - Trade Name: Trobalt/Potiga
      • "One of the more effective, called retigabine, helps open KCNQ potassium channels, the "brakes" that shut down the signaling of overly excited nerves. Unfortunately, retigabine has awful side effects. Because of this, it's usually only given to adults who don't get relief from other epilepsy drugs."
      • "There are five different kinds of KCNQ potassium channels in the body, but only two are important in epilepsy and tinnitus: KCNQ2 and KCNQ3. The problem with retigabine is that it acts on other KCNQ potassium channels as well. That's why it has so many unwanted side effects." source
      • Thanos Tzounopoulos from the University of Pittsburgh is also working on an improved version of retigabine but it's still pre-clinical
      XEN1101 and XEN496 haven't been tested for tinnitus but potassium channels might be a target for pharmacological treatments for tinnitus:
      • Like Like x 3
      • Informative Informative x 3
    3. Greg Sacramento

      Greg Sacramento Member Benefactor Ambassador Hall of Fame Advocate

      Tinnitus Since:
      April 2011
      Cause of Tinnitus:
      syringing and now somatic T dental work
      • Like Like x 1

Share This Page